Kelly A. Lindert

Urology

68 Chester St
Arlington, MA 02476

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults.

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults.

Journal: Vaccines

Published: July 02, 2026

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results).

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results).

Journal: Vaccines

Published: January 22, 2026

Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine.

Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine.

Journal: NEJM evidence

Published: November 19, 2025

Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine.

Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine.

Journal: The New England journal of medicine

Published: November 19, 2025

A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults.

A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults.

Journal: Vaccines

Published: January 20, 2025

Deciphering immune responses: a comparative analysis of influenza vaccination platforms.

Deciphering immune responses: a comparative analysis of influenza vaccination platforms.

Journal: Drug discovery today

Published: February 15, 2024

Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials.

Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials.

Journal: Nature communications

Published: September 05, 2023

A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine.

A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine.

Journal: NPJ vaccines

Published: May 06, 2022

Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccine.

Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccine.

Journal: NPJ vaccines

Published: May 06, 2022

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children.

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: February 16, 2019

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older.

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: February 16, 2019

Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study.

Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study.

Journal: Human vaccines & immunotherapeutics

Published: June 21, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026